A big company called Biohaven is doing well, so some important people who work there bought more shares of the company. This means they believe the company will keep doing well and the stock price will go up. There are also other companies that these important people are buying shares in because they think those companies will do well too. Read from source...

- The title is misleading and sensationalist, implying that insiders are buying Biohaven stock in large quantities, while only mentioning one director who bought a little over $900k worth of shares.
- The article does not provide any context or background information about Biohaven, its business model, or its pipeline of products and trials.
- The article does not explain why the company priced a 5.6 million share offering at $41 per share on April 18, nor how this affects the stock price or the market sentiment.
- The article does not mention any other insiders who bought Biohaven shares, or compare their purchases to previous transactions or average trading volumes.
- The article does not analyze the potential risks and challenges that Biohaven faces as a clinical-stage biopharmaceutical company, nor how it plans to overcome them and achieve its goals.
- The article does not provide any sources or references for the claims and statements made about insider purchases, the stock price, or the market trends.

Given the information provided in the article, it seems that there are four stocks that insiders are buying, which could indicate potential growth opportunities. However, these are not definitive recommendations and should be considered alongside other factors such as personal financial goals, risk tolerance, and market conditions. Here are some key points to consider for each of the mentioned stocks:

1. Biohaven Ltd. (NYSE:BHVN) - The company is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing life-changing treatments in immunology, neuroscience, and oncology. It has recently priced a 5.609 million share offering at $41 per share, which could indicate confidence in the company's prospects or potential value in the stock. However, it is important to note that insider purchases do not guarantee success, and there may be risks associated with investing in a clinical-stage biopharmaceutical company.
2. authID Inc. (OTCQB:ATHD) - The company provides identity authentication solutions for various industries such as finance, healthcare, government, and education. It is currently trading at around $5 per share, which could indicate potential value or a turnaround in the company's fortunes. However, it is important to note that the stock has been volatile and there may be risks associated with investing in a smaller, less-established company.
3. BioXcel Therapeutics Inc. (NASDAQ:BTAI) - The company is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and immune-oncology diseases. It has recently announced a partnership with Takeda Pharmaceutical Company Limited to develop and commercialize BXCL501, an investigational sublingual film formulation of dexamethasone, for the treatment of agitation in schizophrenia and bipolar disorder. This could indicate potential growth opportunities for the company, but it is important to note that there may be risks associated with investing in a clinical-stage biopharmaceutical company.
4. Innoviva Inc. (NASDAQ:INNA) - The company is a biopharmaceutical company focused on developing and commercializing therapies for respiratory diseases. It has recently announced the completion of its previously announced secondary offering of 6,825,000 shares of its common stock at $17 per share, which could indicate confidence in the company's prospects or potential value in the stock. However, it is important to note that